Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application

References

• Louis DN, von Deimling A, Cavenee WK. 1. Diffuse astrocytic and oligodendroglial tumours. Louis DN, Ohgaki H, Wiestler OD, et al., editors. WHO classification of tumours of the central nervous system Revised 4th IARC, Lyon, France; 2016. p. 15–78
   Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
   PubMed Web of Science ®Google Scholar
• Jones C, Karajannis MA, Jones DTW, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19(2):153–161.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–670.
   PubMed Web of Science ®Google Scholar
• Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howley PM, editors. Fields Virology. 2013 ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 1823–1897.
   Google Scholar
• Peters C, Rabkin SD. Designing herpes viruses as oncolytics. Mol Ther Oncolytics. 2015;2:15010.
   PubMed Web of Science ®Google Scholar
• Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252(5007):854–856.
   PubMed Web of Science ®Google Scholar
• Ning J, Wakimoto H. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front Microbiol. 2014;5:303.
   PubMed Web of Science ®Google Scholar
• Grigg C, Blake Z, Gartrell R, et al. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin Oncol. 2016;43(6):638–646.
   PubMed Web of Science ®Google Scholar
• Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 2004;11(22):1648–1658.
   PubMed Web of Science ®Google Scholar
• Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 2002;9(6):398–406.
   PubMed Web of Science ®Google Scholar
• Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716\) in patients with recurrent malignant glioma. Gene Ther. 2000;7(10):859–866.
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938–943.
   PubMed Web of Science ®Google Scholar
• Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98(11):6396–6401.
   PubMed Web of Science ®Google Scholar
• Terada K, Wakimoto H, Tyminski E, et al. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 2006;13(8):705–714.
   PubMed Web of Science ®Google Scholar
• Hardcastle J, Kurozumi K, Dmitrieva N, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther. 2010;18(2):285–294.
   PubMed Web of Science ®Google Scholar
• Gambini E, Reisoli E, Appolloni I, et al. Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther. 2012;20(5):994–1001.
   PubMed Web of Science ®Google Scholar
• Reisoli E, Gambini E, Appolloni I, et al. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Genet Ther. 2012;19(11):788–795.
   PubMed Web of Science ®Google Scholar
• Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012;104(1):42–55.
   PubMedGoogle Scholar
• Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472–3481.
   PubMed Web of Science ®Google Scholar
• Mazzacurati L, Marzulli M, Reinhart B, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther. 2015;23(1):99–107.
   PubMed Web of Science ®Google Scholar
• Delwar ZM, Liu G, Kuo Y, et al. Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Oncotarget. 2016;7(19):28658–28669.
   PubMedGoogle Scholar
• Alessandrini F, Menotti L, Avitabile E, et al. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model. Oncogene. 2019.
   PubMed Web of Science ®Google Scholar
• Kambara H, Okano H, Chiocca EA, et al. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005;65(7):2832–2839.
   PubMed Web of Science ®Google Scholar
• Nakashima H, Nguyen T, Kasai K, et al. Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma. Clin Cancer Res. 2018;24(11):2574–2584.
   PubMed Web of Science ®Google Scholar
• Cassady KA. Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection. J Virol. 2005;79(14):8707–8715.
   PubMed Web of Science ®Google Scholar
• Friedman GK, Nan L, Haas MC, et al. Gamma(1)34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther. 2015;22(4):356.
   PubMed Web of Science ®Google Scholar
• Cassady KA, Bauer DF, Roth J, et al. Pre-clinical assessment of C134, a chimeric oncolytic herpes simplex virus, in mice and non-human Primates. Mol Ther Oncolytics. 2017;5:1–10.
   PubMed Web of Science ®Google Scholar
• Tamura K, Wakimoto H, Agarwal AS, et al. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013;21(1):68–77.
   PubMed Web of Science ®Google Scholar
• Jahan N, Lee JM, Shah K, et al. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer. 2017;141(8):1671–1681.
   PubMed Web of Science ®Google Scholar
• Xu B, Ma R, Russell L, et al. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nat Biotechnol. 2018;37:45–54.
   PubMedGoogle Scholar
• Kanai R, Rabkin SD. Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol. 2013;2(2):129–142.
   PubMedGoogle Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–691.
   PubMed Web of Science ®Google Scholar
• Otsuki A, Patel A, Kasai K, et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther. 2008;16(9):1546–1555.
   PubMed Web of Science ®Google Scholar
• Nakashima H, Kaufmann JK, Wang PY, et al. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest. 2015;125(11):4269–4280.
   PubMed Web of Science ®Google Scholar
• Bolyard C, Yoo JY, Wang PY, et al. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clin Cancer Res. 2014;20(24):6479–6494.
   PubMed Web of Science ®Google Scholar
• Ning J, Wakimoto H, Peters C, et al. Rad51 degradation: role in oncolytic virus-poly(ADP-Ribose) polymerase inhibitor combination therapy in glioblastoma. J Natl Cancer Inst. 2017;109(3):1–13.
   PubMedGoogle Scholar
• Yoo JY, Hurwitz BS, Bolyard C, et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clin Cancer Res. 2014;20(14):3787–3798.
   PubMed Web of Science ®Google Scholar
• Yoo JY, Haseley A, Bratasz A, et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and “Vstat120"-expressing oncolytic virus. Mol Ther. 2012;20(2):287–297.
   PubMed Web of Science ®Google Scholar
• Yoo JY, Jaime-Ramirez AC, Bolyard C, et al. Bortezomib treatment sensitizes oncolytic HSV-1-treated tumors to NK cell immunotherapy. Clin Cancer Res. 2016;22(21):5265–5276.
   PubMed Web of Science ®Google Scholar
• Kurozumi K, Hardcastle J, Thakur R, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 2007;99(23):1768–1781.
   PubMedGoogle Scholar
• Zhang W, Fulci G, Wakimoto H, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013;15(6):591–599.
   PubMed Web of Science ®Google Scholar
• Zhang W, Fulci G, Buhrman JS, et al. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther. 2012;20(1):37–45.
   PubMed Web of Science ®Google Scholar
• Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA. 2013;110(29):12006–12011.
   PubMed Web of Science ®Google Scholar
• Saha D, Wakimoto H, Peters CW, et al. Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. Clin Cancer Res. 2018;24(14):3409–3422.
   PubMed Web of Science ®Google Scholar
• Ikushima H, Todo T, Ino Y, et al. TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009;5(5):504–514.
   PubMed Web of Science ®Google Scholar
• Penuelas S, Anido J, Prieto-Sanchez RM, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315–327.
   PubMed Web of Science ®Google Scholar
• Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331(2):131–138.
   PubMed Web of Science ®Google Scholar
• Esaki S, Nigim F, Moon E, et al. Blockade of transforming growth factor-beta signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017;141(11):2348–2358.
   PubMed Web of Science ®Google Scholar
• Kanai R, Wakimoto H, Martuza RL, et al. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011;17(11):3686–3696.
   PubMed Web of Science ®Google Scholar
• Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4(124):124ra27.
   PubMed Web of Science ®Google Scholar
• Safdie F, Brandhorst S, Wei M, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One. 2012;7(9):e44603.
   PubMed Web of Science ®Google Scholar
• Esaki S, Rabkin SD, Martuza RL, et al. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016;6(2):300–311.
   PubMed Web of Science ®Google Scholar
• Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA. 2006;103(34):12873–12878.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5(8):881–887.
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Fulci G, Tyminski E, et al. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide‘s enhancement of viral oncolysis. Genet Ther. 2004;11(2):214–223.
   PubMed Web of Science ®Google Scholar
• Han J, Chen X, Chu J, et al. TGFbeta treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Res. 2015;75(24):5273–5282.
   PubMed Web of Science ®Google Scholar
• Kim Y, Yoo JY, Lee TJ, et al. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci USA. 2018;115(19):4927–4932.
   PubMed Web of Science ®Google Scholar
• Dai HS, Griffin N, Bolyard C, et al. The Fc domain of immunoglobulin is sufficient to bridge NK cells with virally infected cells. Immunity. 2017;47(1):159–70e10.
   PubMed Web of Science ®Google Scholar
• Meisen WH, Wohleb ES, Jaime-Ramirez AC, et al. The impact of macrophage- and microglia-secreted TNFalpha on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clin Cancer Res. 2015;21(14):3274–3285.
   PubMed Web of Science ®Google Scholar
• Das S, Owen KA, Ly KT, et al. Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram-negative bacteria. Proc Natl Acad Sci USA. 2011;108(5):2136–2141.
   PubMed Web of Science ®Google Scholar
• Bolyard C, Meisen WH, Banasavadi-Siddegowda Y, et al. BAI1 orchestrates macrophage inflammatory response to HSV infection-implications for oncolytic viral therapy. Clin Cancer Res. 2017;23(7):1809–1819.
   PubMed Web of Science ®Google Scholar
• Thorne AH, Meisen WH, Russell L, et al. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther. 2014;22(9):1678–1687.
   PubMed Web of Science ®Google Scholar
• Delwar ZM, Kuo Y, Wen YH, et al. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer Res. 2018;78(3):718–730.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015;17(Suppl 7):vii9–vii14.
   PubMed Web of Science ®Google Scholar
• Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459–1468.
   PubMed Web of Science ®Google Scholar
• Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32(2):253–67e5.
   PubMed Web of Science ®Google Scholar
• Passaro C, Alayo Q, De Laura I, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res. 2019;25(1):290–299.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–88.
   PubMed Web of Science ®Google Scholar
• Russell L, Swanner J, Jaime-Ramirez AC, et al. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nat Commun. 2018;9(1):5006.
   PubMed Web of Science ®Google Scholar
• Ghonime MG, Jackson J, Shah A, et al. Chimeric HCMV/HSV-1 and Deltagamma134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018;11(1):86–93.
   PubMed Web of Science ®Google Scholar
• Hong B, Muili K, Bolyard C, et al. Suppression of HMGB1 released in the glioblastoma tumor microenvironment reduces tumoral edema. Mol Ther Oncolytics. 2019;12:93–102.
   PubMed Web of Science ®Google Scholar
• Roy DG, Bell JC. Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytics Virother. 2013;2:47–56.
   PubMedGoogle Scholar
• Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed Ex for cancer therapy. Mol Ther. 2009;17(10):1667–1676.
   PubMed Web of Science ®Google Scholar
• Duebgen M, Martinez-Quintanilla J, Tamura K, et al. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014;106(6):dju090.
   PubMedGoogle Scholar
• Lathia JD, Mack SC, Mulkearns-Hubert EE, et al. Cancer stem cells in glioblastoma. Genes Dev. 2015;29(12):1203–1217.
   PubMed Web of Science ®Google Scholar
• Peters C, Paget M, Tshilenge KT, et al. Restriction of replication of oncolytic herpes simplex virus with a deletion of γ34.5 in glioblastoma stem-like cells. J Virol. 2018;92(15).
   Google Scholar
• Foreman PM, Friedman GK, Cassady KA, et al. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics. 2017;14(2):333–344.
   PubMed Web of Science ®Google Scholar
• Whisenhunt TR Jr., Rajneesh KF, Hackney JR, et al. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytics Virother. 2015;4:33–38.
   PubMed Web of Science ®Google Scholar
• Markert JM, Razdan SN, Kuo H-C, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014;22(5):1048–1055.
   PubMed Web of Science ®Google Scholar
• Waters AM, Johnston JM, Reddy AT, et al. Rationale and design of a phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumors. Hum Genet Ther Clin Dev. 2017;28(1):7–16.
   PubMed Web of Science ®Google Scholar
• Bernstock JD, Wright Z, Bag AK, et al. Stereotactic placement of intratumoral catheters for continuous infusion delivery of herpes simplex virus −1 G207 in pediatric malignant supratentorial brain tumors. World Neurosurg. 2019;122:e1592–e8.
   PubMed Web of Science ®Google Scholar
• Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA. 2000;97(5):2208–2213.
   PubMed Web of Science ®Google Scholar
• Friedman GK, Bernstock JD, Chen D, et al. Enhanced sensitivity of patient-derived pediatric high-grade brain tumor xenografts to oncolytic HSV-1 virotherapy correlates with nectin-1 expression. Sci Rep. 2018;8(1):13930.
   PubMed Web of Science ®Google Scholar
• Roth JC, Cassady KA, Cody JJ, et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev. 2014;25(1):16–27.
   PubMed Web of Science ®Google Scholar
• Patel DM, Foreman PM, Nabors LB, et al. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum Genet Ther Clin Dev. 2016;27(2):69–78.
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza MC, Cho CF, et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–849.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674–686.
   PubMed Web of Science ®Google Scholar
• Marchini A, Scott EM, Rommelaere J. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade. Viruses. 2016;8(1).
   PubMed Web of Science ®Google Scholar
• Nakashima H, Nguyen T, Chiocca EA. Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytics Virother. 2015;4:183–191.
   PubMed Web of Science ®Google Scholar
• Shi G, Yang Q, Zhang Y, et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther. 2019;27(1):244–260.
   PubMed Web of Science ®Google Scholar